Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- No Impact from Coronavirus Outbreak Seen with February Detailing Number: Intage
April 10, 2020
- Indian Export Restriction Lifted, but Japan Imports Still Stalled
April 10, 2020
- Astellas Boosts COVID-19 Measures after State of Emergency Declared; Daiichi Sankyo Partially Pausing Trials
April 10, 2020
- Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
- MSD Introduces AI Chatbot for Information Provisioning of Keytruda
April 9, 2020
- FunPep Joins AnGes, Osaka Univ. Partnership to Develop Novel Coronavirus Vaccine
April 9, 2020
- Chugai to Launch Actemra PIII Trial for Coronavirus
April 9, 2020
- Roche Diagnostics Launches Coronavirus Test in Japan
April 8, 2020
- Japan Ethical Drug Sales Up 0.1% in February: Crecon
April 8, 2020
- Takeda’s NSCLC Med Alunbrig Bags EU Nod for 1st-Line Use
April 8, 2020
- Daiichi Sankyo Sets Up Task Force to Develop COVID-19 Vaccine, Treatment
April 8, 2020
- Kyowa Pharma Joins Forces with German neuroCare Group in CNS
April 8, 2020
- Pfizer Japan Extends Work-from-Home through May 6
April 7, 2020
- Takeda, CSL, Other Firms Join Hands to Develop Unbranded Immunoglobulin for COVID-19
April 7, 2020
- MSD Japan to Get Women’s Health Spinoff Organon Up and Running in October: Chief
April 7, 2020
- Japan Ethical Drug Sales Up 3.4% in FY2019: Encise
April 7, 2020
- Rush to BCG Vaccine for COVID-19 Leads to Curbs on Shipments
April 7, 2020
- Kowa Sues Towa Again over Livalo Generics, Seeking Over 4.8 Billion Yen in Additional Damages for FY2017
April 7, 2020
- Astellas, Bandai Namco Link Up on Codevelopment of Exercise Support App
April 7, 2020
- Meiji Scoops Up Marketing Rights for Mochida’s Epadel in Vietnam
April 7, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…